AR113778A2 - Composición farmacéutica que comprende una sal de difosfato de n-[6-(cis-2,6-dimetilmorfolin-4-il)piridin-3-il]-2-metil-4’-(trifluormetoxi)[1,1’-bifenil]-3-carboxamida - Google Patents

Composición farmacéutica que comprende una sal de difosfato de n-[6-(cis-2,6-dimetilmorfolin-4-il)piridin-3-il]-2-metil-4’-(trifluormetoxi)[1,1’-bifenil]-3-carboxamida

Info

Publication number
AR113778A2
AR113778A2 ARP180103036A ARP180103036A AR113778A2 AR 113778 A2 AR113778 A2 AR 113778A2 AR P180103036 A ARP180103036 A AR P180103036A AR P180103036 A ARP180103036 A AR P180103036A AR 113778 A2 AR113778 A2 AR 113778A2
Authority
AR
Argentina
Prior art keywords
carboxamide
pyridin
biphenyl
cis
methyl
Prior art date
Application number
ARP180103036A
Other languages
English (en)
Original Assignee
Sun Pharma Global Fze
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41228716&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR113778(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharma Global Fze filed Critical Sun Pharma Global Fze
Publication of AR113778A2 publication Critical patent/AR113778A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Composición farmacéutica que comprende: (a) una cantidad terapéuticamente efectiva de una sal de difosfato de N-[6-(cis-2,6-dimetilmorfolin-4-il)piridin-3-il]-2-metil-4’-(trifluormetoxi)[1,1’-bifenil]-3-carboxamida; y (b) al menos un portador, diluyente, vehículo o excipiente farmacéuticamente aceptable.
ARP180103036A 2008-09-17 2018-10-18 Composición farmacéutica que comprende una sal de difosfato de n-[6-(cis-2,6-dimetilmorfolin-4-il)piridin-3-il]-2-metil-4’-(trifluormetoxi)[1,1’-bifenil]-3-carboxamida AR113778A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9758008P 2008-09-17 2008-09-17

Publications (1)

Publication Number Publication Date
AR113778A2 true AR113778A2 (es) 2020-06-10

Family

ID=41228716

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP090103530A AR073591A1 (es) 2008-09-17 2009-09-15 Sales de n-[6-(cis-2,6-dimetil-morfolin-4-il)-piridin-3-il]-2-metil-4'-(trifluorometoxi)-[1,1'-bifenil]-3-carboxamida,composiciones farmaceuticas que las contienen,utiles para el tratamiento de carcinomas.
ARP180103036A AR113778A2 (es) 2008-09-17 2018-10-18 Composición farmacéutica que comprende una sal de difosfato de n-[6-(cis-2,6-dimetilmorfolin-4-il)piridin-3-il]-2-metil-4’-(trifluormetoxi)[1,1’-bifenil]-3-carboxamida

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP090103530A AR073591A1 (es) 2008-09-17 2009-09-15 Sales de n-[6-(cis-2,6-dimetil-morfolin-4-il)-piridin-3-il]-2-metil-4'-(trifluorometoxi)-[1,1'-bifenil]-3-carboxamida,composiciones farmaceuticas que las contienen,utiles para el tratamiento de carcinomas.

Country Status (39)

Country Link
US (3) US8063043B2 (es)
EP (1) EP2342198B1 (es)
JP (2) JP4897938B2 (es)
KR (2) KR101129088B1 (es)
CN (1) CN102159570B (es)
AR (2) AR073591A1 (es)
AU (1) AU2009293444B2 (es)
BR (2) BRPI0918629B8 (es)
CA (1) CA2736751C (es)
CL (1) CL2011000551A1 (es)
CO (1) CO6351744A2 (es)
CR (1) CR20110126A (es)
CU (1) CU23860B1 (es)
DK (1) DK2342198T3 (es)
DO (1) DOP2011000082A (es)
EA (1) EA020048B1 (es)
EC (1) ECSP11010985A (es)
ES (1) ES2418485T3 (es)
GE (1) GEP20125592B (es)
HK (1) HK1156628A1 (es)
HN (1) HN2011000745A (es)
HR (1) HRP20130597T1 (es)
IL (1) IL211412A (es)
JO (1) JO2889B1 (es)
MA (1) MA32717B1 (es)
MX (1) MX2011002805A (es)
MY (1) MY151100A (es)
NI (1) NI201100051A (es)
NZ (1) NZ591420A (es)
PE (1) PE20110292A1 (es)
PL (1) PL2342198T3 (es)
PT (1) PT2342198E (es)
SI (1) SI2342198T1 (es)
SM (1) SMT201300072B (es)
SV (1) SV2011003857A (es)
TW (1) TWI367883B (es)
UA (1) UA103049C2 (es)
WO (1) WO2010033481A1 (es)
ZA (1) ZA201101579B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
CN101993415B (zh) * 2010-09-15 2013-08-14 北京韩美药品有限公司 作为Hedgehog通路抑制剂的化合物以及包含该化合物的药物组合物及其应用
US9943520B2 (en) 2013-02-25 2018-04-17 Sun Pharma Global Fze Oral formulation and suspension of an oncology drug
WO2015092720A1 (en) * 2013-12-19 2015-06-25 Novartis Ag Metabolites of sonidegib (lde225)
EP3279198B1 (en) * 2015-03-30 2020-01-01 Crystal Pharmatech Co., Ltd Crystal form of n-[6-(cis form-2,6-dimethylmorpholine-4-group)pyridine-3- group]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3- formamide monophosphate, and preparation method therefor
US10369147B2 (en) 2015-06-04 2019-08-06 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
KR20230042756A (ko) 2016-03-15 2023-03-29 오리존 지노믹스 에스.에이. 고형 종양의 치료에 사용하기 위한 lsd1 억제제의 조합물
WO2017163258A1 (en) * 2016-03-22 2017-09-28 Msn Laboratories Private Limited Process for the preparation of n-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2- methyl-4'-(trifiuoromethoxy) [1,1' -biphenyi]-3-carboxamide and its polymorphs thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080007520A (ko) * 2003-10-02 2008-01-21 파마시아 앤드 업존 캄파니 엘엘씨 피롤-치환된 인돌리논 화합물의 염 및 다형체
GB0412468D0 (en) * 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
UA93548C2 (uk) * 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
PE20080948A1 (es) * 2006-07-25 2008-09-10 Irm Llc Derivados de imidazol como moduladores de la senda de hedgehog

Also Published As

Publication number Publication date
US20110178085A1 (en) 2011-07-21
TWI367883B (en) 2012-07-11
JP2012502912A (ja) 2012-02-02
MY151100A (en) 2014-04-15
CU20110055A7 (es) 2011-12-28
EP2342198A1 (en) 2011-07-13
BRPI0918629A2 (pt) 2020-10-27
EA020048B1 (ru) 2014-08-29
AU2009293444B2 (en) 2012-03-15
US8063043B2 (en) 2011-11-22
US20120214810A1 (en) 2012-08-23
KR20120015363A (ko) 2012-02-21
JP4897938B2 (ja) 2012-03-14
TW201016686A (en) 2010-05-01
IL211412A (en) 2014-07-31
PE20110292A1 (es) 2011-05-17
KR101129088B1 (ko) 2012-03-23
CA2736751C (en) 2012-10-23
PL2342198T3 (pl) 2013-08-30
BRPI0918629B1 (pt) 2021-04-13
AR073591A1 (es) 2010-11-17
ECSP11010985A (es) 2011-05-31
CN102159570A (zh) 2011-08-17
BRPI0918629B8 (pt) 2021-05-25
CL2011000551A1 (es) 2011-07-15
WO2010033481A1 (en) 2010-03-25
IL211412A0 (en) 2011-05-31
HRP20130597T1 (en) 2013-07-31
ES2418485T3 (es) 2013-08-14
ZA201101579B (en) 2011-11-30
MA32717B1 (fr) 2011-10-02
SI2342198T1 (sl) 2013-07-31
DOP2011000082A (es) 2011-04-15
KR20110056325A (ko) 2011-05-26
AU2009293444A1 (en) 2010-03-25
PT2342198E (pt) 2013-07-10
CR20110126A (es) 2011-04-27
UA103049C2 (uk) 2013-09-10
CO6351744A2 (es) 2011-12-20
US20120035174A1 (en) 2012-02-09
BR122020009045B1 (pt) 2022-08-02
CU23860B1 (es) 2013-02-26
EP2342198B1 (en) 2013-04-03
DK2342198T3 (da) 2013-07-01
NI201100051A (es) 2011-09-08
NZ591420A (en) 2012-07-27
GEP20125592B (en) 2012-07-25
MX2011002805A (es) 2011-04-11
JO2889B1 (en) 2015-03-15
JP2012097104A (ja) 2012-05-24
SMT201300072B (it) 2013-09-06
HN2011000745A (es) 2014-01-06
HK1156628A1 (es) 2012-06-15
SV2011003857A (es) 2011-05-16
BR122020009045A2 (pt) 2020-11-10
CN102159570B (zh) 2014-01-15
EA201100501A1 (ru) 2011-10-31
CA2736751A1 (en) 2010-03-25

Similar Documents

Publication Publication Date Title
AR113778A2 (es) Composición farmacéutica que comprende una sal de difosfato de n-[6-(cis-2,6-dimetilmorfolin-4-il)piridin-3-il]-2-metil-4’-(trifluormetoxi)[1,1’-bifenil]-3-carboxamida
AR109423A2 (es) Sal moduladora de la vía hedgehog
UY32062A (es) Inhibidores de beta-secretasa
GT200600496A (es) Sales, profarmacos y formulaciones de 1-[5-(4-amino-7-isopropil-7h-pirrolo[2,3-d]piirimidin-5-carbonil)-2-metoxi-feil]-3-(2,4-dicloro-fenil)-urea.
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
NO20090628L (no) Pyridizinon derivativater
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
MA32812B1 (fr) Composition pharmaceutique d'un inhibiteur puissant du vhc pour une administration orale
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
MX2009004798A (es) Tratamiento de los trastornos generalizados del desarrollo.
PE20121820A1 (es) (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida, formas de sales novedosas de ella, y metodos de uso de ella
WO2013003629A3 (en) Methods and compositions for inhibition of bone resorption
BR112014001600A2 (pt) composto inibidor do trajeto de sinalização notch
RS53209B (en) PHARMACEUTICAL COMPOSITION FOR VIRAL HEPATITIS C PROTEASE INHIBITOR
ECSP099350A (es) COMPUESTOS DE TETRAHIDROCICLOPENTA[b]INDOL COMO MODULADORES
UY32174A (es) Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones
UA96449C2 (en) Stable laquinimod preparations
UY30438A1 (es) Derivados n-sustituidos de 5-halo-4-[2-alquil-1-sustituidos-1h-imidazol-5-il]pirimidin-2-amina, composiciones-procesos para su preparacion y usos
BR112014010401A2 (pt) inibidores do vírus da hepatite c rod-like que contêm o fragmento {2-[4-(bifenil-4-il)-1h-imidazo-2-il] pirrolidina-1-carbonilmetil}amina
BR112013032711A2 (pt) composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase
UY30460A1 (es) Compuestos terapéuticos
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
CR10422A (es) Formulaciones de dosificacion solida
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций

Legal Events

Date Code Title Description
FC Refusal